相关临床试验
12
4 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1847
进行中（未招募）
2
16.7%
已完成
5
41.7%
尚未招募
2
16.7%
招募中
2
16.7%
终止
1
8.3%
暂无批准数据
- Vascarta and CUNY published preclinical data showing STO-1, a curcumin-paclitaxel hybrid molecule, achieved 67% long-term survival in glioblastoma-bearing mice with several animals experiencing complete tumor clearance. - The first-in-class drug candidate selectively targets tumor-associated immune cells while avoiding harmful autoimmune reactions commonly seen with other immunotherapies. - STO-1 works by reprogramming deactivated tumor-associated immune cells to attack glioblastoma tumors while preserving healthy immune function. - The breakthrough offers potential for treating the most aggressive form of brain cancer, which affects over 13,000 Americans annually with poor current treatment outcomes.
- Researchers at the City University of New York have identified synthetic carbohydrate receptors that successfully blocked infection from seven different viruses across five unrelated families, including Ebola, Marburg, and SARS-CoV-2. - In critical testing, 90 percent of mice infected with SARS-CoV-2 survived when treated with the lead compound, compared to none in the control group. - The compounds work by targeting viral envelope glycans, sugar molecules that are structurally conserved across unrelated viral families and represent a novel mechanism of action. - Phase I clinical trials are anticipated to begin in 2028, potentially offering the world's first broad-spectrum antiviral for immediate deployment against future pandemic threats.
